Rigel Pharmaceuticals Inc (RIGL)
1.08
+0.03
(+2.86%)
USD |
NASDAQ |
Apr 19, 16:00
1.075
0.00 (0.00%)
After-Hours: 20:00
Rigel Pharmaceuticals Cash from Investing (TTM): -4.297M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -4.297M |
September 30, 2023 | 21.18M |
June 30, 2023 | 32.80M |
March 31, 2023 | 50.92M |
December 31, 2022 | 72.78M |
September 30, 2022 | 60.67M |
June 30, 2022 | 5.815M |
March 31, 2022 | -64.94M |
December 31, 2021 | -80.04M |
September 30, 2021 | -77.81M |
June 30, 2021 | -13.89M |
March 31, 2021 | 30.54M |
December 31, 2020 | 47.47M |
September 30, 2020 | 31.14M |
June 30, 2020 | 11.32M |
March 31, 2020 | 1.878M |
December 31, 2019 | -23.66M |
September 30, 2019 | -13.95M |
June 30, 2019 | 2.203M |
March 31, 2019 | 0.673M |
December 31, 2018 | 24.96M |
September 30, 2018 | -12.37M |
June 30, 2018 | -20.66M |
March 31, 2018 | 3.895M |
December 31, 2017 | -19.47M |
Date | Value |
---|---|
September 30, 2017 | 17.88M |
June 30, 2017 | 20.71M |
March 31, 2017 | 31.50M |
December 31, 2016 | 24.88M |
September 30, 2016 | 35.52M |
June 30, 2016 | 55.77M |
March 31, 2016 | 28.33M |
December 31, 2015 | 44.61M |
September 30, 2015 | 48.78M |
June 30, 2015 | 25.43M |
March 31, 2015 | 61.98M |
December 31, 2014 | 62.93M |
September 30, 2014 | 69.52M |
June 30, 2014 | 77.12M |
March 31, 2014 | 57.07M |
December 31, 2013 | 72.40M |
September 30, 2013 | -59.37M |
June 30, 2013 | -55.20M |
March 31, 2013 | -39.43M |
December 31, 2012 | -39.03M |
September 30, 2012 | 87.07M |
June 30, 2012 | 56.50M |
March 31, 2012 | -74.45M |
December 31, 2011 | -62.85M |
September 30, 2011 | -104.64M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-80.04M
Minimum
Dec 2021
72.78M
Maximum
Dec 2022
4.743M
Average
5.815M
Median
Jun 2022
Cash from Investing (TTM) Benchmarks
Nektar Therapeutics | 139.56M |
Avid Bioservices Inc | -57.64M |
Stereotaxis Inc | 19.76M |
Cara Therapeutics Inc | 43.46M |
Blueprint Medicines Corp | 274.04M |